Levodopa-induced dyskinesia in Parkinson's disease: pathogenesis and emerging treatment strategies

DK Kwon, M Kwatra, J Wang, HS Ko - Cells, 2022 - mdpi.com
The most commonly used treatment for Parkinson's disease (PD) is levodopa, prescribed in
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …

Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments

P Maiti, J Manna, GL Dunbar - Translational neurodegeneration, 2017 - Springer
Gradual degeneration and loss of dopaminergic neurons in the substantia nigra, pars
compacta and subsequent reduction of dopamine levels in striatum are associated with …

[HTML][HTML] Parkinson's disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis

G DeMaagd, A Philip - Pharmacy and therapeutics, 2015 - ncbi.nlm.nih.gov
Parkinson’s Disease and Its Management - PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search …

Levodopa‐induced dyskinesia in Parkinson disease: current and evolving concepts

AJ Espay, F Morgante, A Merola, A Fasano… - Annals of …, 2018 - Wiley Online Library
Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic
mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa …

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

MF Bastide, WG Meissner, B Picconi, S Fasano… - Progress in …, 2015 - Elsevier
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

SH Fox, R Katzenschlager, SY Lim… - Movement …, 2011 - Wiley Online Library
The objective was to update previous evidence‐based medicine reviews of treatments for
motor symptoms of Parkinson's disease published between 2002 and 2005. Level I …

The scientific and clinical basis for the treatment of Parkinson disease (2009)

CW Olanow, MB Stern, K Sethi - Neurology, 2009 - AAN Enterprises
Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many
as 1–2% of persons aged 60 years and older. With the aging of the population, the …

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

P Huot, TH Johnston, JB Koprich, SH Fox… - Pharmacological …, 2013 - ASPET
l-3, 4-Dihydroxyphenylalanine (l-DOPA) remains the most effective symptomatic treatment of
Parkinson's disease (PD). However, long-term administration of l-DOPA is marred by the …

Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review):[RETIRED] Report of the Quality Standards …

R Pahwa, SA Factor, KE Lyons, WG Ondo, G Gronseth… - Neurology, 2006 - AAN Enterprises
Objective: To make evidence-based treatment recommendations for the medical and
surgical treatment of patients with Parkinson disease (PD) with levodopa-induced motor …

Levodopa‐induced dyskinesias

G Fabbrini, JM Brotchie, F Grandas… - … : official journal of the …, 2007 - Wiley Online Library
Levodopa‐induced dyskinesias (LID) are common and difficult to treat. This review focuses
on three issues related to LID: clinical features, classification and rating, pathophysiology …